The Turing-Roche strategic partnership is a collaboration in advanced analytics between Roche and the Turing, focused on enabling the transformative benefits of personalised healthcare to become a reality for patients around the world. The Turing-Roche knowledge share series brings together members of Roche and Turing's networks to showcase partnership research and share knowledge. 

This June 2023 knowledge share will be on the topic of personalised medicine in the face of multi-scale heterogeneity. Complex pathologies often display heterogeneity at multiple scales. Understanding this heterogeneity is essential to design and evaluate therapies in an increasingly personalised manner, with profound implications for drug discovery, biomarker identification and outcome assessment.

The event speaker will be Turing-Roche Senior Postdoctoral Research Associate Christopher Banerji. Chris will use the example of facioscapulohumeral muscular dystrophy (FSHD), a complex rare-disease, as a prototype for muti-scale heterogeneity in pathology. He will show that integrating datasets at diverse scales, coupled with appropriate mathematical, clinical and cell biological analysis leads to important and novel insights into therapeutic development, biomarker discovery and lifestyle risk-factor identification.

This is an online event. For further details and to register, please visit: The Turing-Roche Knowledge Share Series: Personalised Medicine in the face of multi-scale heterogeneity | The Alan Turing Institute